The contribution of neuropathology to multiple sclerosis research.

MULTIPLE sclerosis; NEUROLOGICAL disorders; NEUROMYELITIS optica; DEMYELINATION; MYELIN oligodendrocyte glycoprotein; MYELIN sheath diseases

Background and purpose: Neuropathology plays a major role in deciphering disease mechanisms in multiple sclerosis (MS). This review article describes recent advances in neuropathological research related to inflammatory demyelinating diseases. Methods: A retrospective review of neuropathological studies published during the last two decades was conducted. Results: The importance of neuropathology is generally seen in its contribution to the diagnosis of diseases of the nervous system and, in particular, in neuro‐oncology. However, when it also includes analysis of the global three‐dimensional extension of brain damage and the temporal sequence of lesion evolution and relates this to molecular changes in the lesions, it offers the potential to decipher disease pathogenesis and to contribute to the development of effective and causative treatments. In MS research, neuropathology has been essential in discriminating the disease from other inflammatory autoimmune or demyelinating diseases, such as neuromyelitis optica spectrum disorders (NMOSD) or myelin oligodendrocyte glycoprotein antibody‐associated disease (MOGAD). It defined the hallmark of chronic progressive disease in MS patients as slowly expanding tissue damage, which occurs not only within and around lesions but also in the normal appearing white and gray matter. It showed that these changes occur in the course of a tissue‐resident immune response within the central nervous system, involving tissue‐resident effector memory cells and plasma cells. Molecular studies in neuropathologically defined micro‐dissected MS lesions identified a cascade of oxidative injury, mitochondrial damage and subsequent virtual hypoxia as a major pathway of tissue injury in MS. Conclusions: The results of these studies were highly relevant for the identification of potential therapeutic targets in MS patients and the design of pivotal clinical trials. [ABSTRACT FROM AUTHOR]

Copyright of European Journal of Neurology is the property of Wiley-Blackwell and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)